Ensysce Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · La Jolla, CA
ENSC chart
What traders are saying about $ENSC
Latest postsEnsysce Biosciences, Inc. news
- ENSC Q3'26 Earnings: revenue estimate is 1.20M USD
TradingView ·
- Ensysce Biosciences Stock Price Forecast. Should You Buy ENSC?
StockInvest.us ·
- Ensysce Biosciences Announces CEO Transition and Director Resignation
The Globe and Mail ·
- Revelation Biosciences, Inc. (REVB) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Ensysce Biosciences Announces Leadership Changes Including CEO to COO Transition Post-2026 Annual Meeting
Kalkine Media ·
- Ensysce Biosciences announces executive leadership changes after annual meeting
Investing.com ·
- Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
Yahoo Finance ·
- Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
Yahoo Finance ·
- Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Yahoo Finance ·
- Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Yahoo Finance ·
- Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
Yahoo Finance ·
- Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
Yahoo Finance ·
Ensysce Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M |
| Net income | -$10.2M | -$8.0M | -$10.6M | – |
| Diluted EPS | $-3.98 | $-11.45 | $-70.40 | $-139.42 |
| Total assets (year end) | $7.5M | $5.6M | $2.7M | $5.9M |
| Cash and equivalents (year end) | $4.3M | $3.5M | $1.1M | $3.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Ensysce Biosciences, Inc.
- Ticker
- ENSC (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1716947
- Former names
- Leisure Acquisition Corp.
Frequently asked questions
What exchange is Ensysce Biosciences, Inc. listed on?
Ensysce Biosciences, Inc. trades on the Nasdaq under the ticker symbol ENSC.
What industry is Ensysce Biosciences, Inc. in?
Ensysce Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Ensysce Biosciences, Inc. headquartered?
Ensysce Biosciences, Inc.'s business address on file with the SEC is in La Jolla, CA.
When does Ensysce Biosciences, Inc.'s fiscal year end?
Ensysce Biosciences, Inc.'s fiscal year ends on December 31.
How much revenue did Ensysce Biosciences, Inc. report?
Ensysce Biosciences, Inc. reported $5.1M in revenue for calendar year 2025, according to its SEC filings.